Goldman Steven M. 4

4 · Dova Pharmaceuticals Inc. · Filed Jun 24, 2019

Form 4

Period: 2019-06-20

Director

Transactions

Exercise/Conversion
Common Stock
2019-06-20$7.32/sh+917$6,712→ 141,697 total
Exercise/Conversion
Stock Option (right to buy)
2019-06-20−917→ 11,000 total
Exercise: $7.32Exp: 2027-05-24→ Common Stock (917 underlying)
Exercise/Conversion
Common Stock
2019-06-20$9.36/sh+833$7,797→ 142,530 total
Exercise/Conversion
Stock Option (right to buy)
2019-06-20−833→ 9,167 total
Exercise: $9.36Exp: 2029-04-25→ Common Stock (833 underlying)

Holdings

Footnotes (3)

[F1]These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose.
[F2]The option vests over a period of three years as follows: (i) one-third of the total shares subject to the option shall vested on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
[F3]Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date.

Documents

1 file